Board approves audited Q4 and FY2026 results with revenue up 21% in Q4 and 17% for FY, PAT up 18% and 15% respectively, with robust margins and ROCE at 33%.
AI Assistant
Ajanta Pharma Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.